non-small-cell lung cancer
Conditions
Interventions
Experimental group:Kanglaite Injection+Pemetrexed/Gemcitabine/Paclitaxel+Platinum
Control Group:Pemetrexed/Gemcitabine/Paclitaxel+Platinum
Sponsors
Guang'anmen Hospital, Chinese Academy of Chinese Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Non-small cell lung cancer patients with stage III-IV initial chemotherapy confirmed by pathology or cytology; 2. Aged 18 to 75 years, male and female; 3. ECOG score 0-2; 4. The estimated survival time is more than 3 months; 5. According to RECIST 1.1 standard, there is at least one measurable lesion. 6. Voluntary participation in research and signing of informed consent, good compliance, with follow-up.
Exclusion criteria
Exclusion criteria: 1. Patients with brain metastasis; 2. Gene test results showed that EGFR or ALK or ROS1 positive or PD-L1 (> 50%) patients. 3. Patients with pleural effusion requiring therapeutic drainage and intrapleural injection of chemotherapeutic drugs; 4. Patients who are using or preparing to use targeted drugs; 5. Patients undergoing or preparing for pulmonary radiotherapy; 6. Patients undergoing or preparing immunotherapy for tumors; 7. Patients undergoing lipid-lowering therapy; 8. Pregnant or lactating women; women of childbearing age and their spouses can not take effective contraceptive measures during the period of clinical research and within 6 months after the end of the study; psychiatric patients; 9. Patients with severe uncontrolled organic lesions or infections, such as decompensated heart, lung and kidney failure, who are unable to tolerate chemotherapy; 10. Patients who received clinical trials of small molecular drugs within 10.28 days or macromolecular drugs within 3 months; 11. Patients known to be allergic or intolerable to drug allergies; 12. Researchers consider other conditions that prevent patients from participating in the trial.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| ORR;One-year survival rate;Quality of life;Cachexia signs;Living ability;blood fat;blood fat;Incidence of adverse reactions;Incidence of adverse reactions; | — |
Countries
China
Contacts
Public ContactJie Li
Guang'anmen Hospital, Chinese Academy of Traditional Chinese Medicine Sciences
Outcome results
None listed